NO20070655L - 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft - Google Patents

2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft

Info

Publication number
NO20070655L
NO20070655L NO20070655A NO20070655A NO20070655L NO 20070655 L NO20070655 L NO 20070655L NO 20070655 A NO20070655 A NO 20070655A NO 20070655 A NO20070655 A NO 20070655A NO 20070655 L NO20070655 L NO 20070655L
Authority
NO
Norway
Prior art keywords
phosphotidylinositol
cancer
treatment
kinase inhibitors
trisubstituted pyrimidines
Prior art date
Application number
NO20070655A
Other languages
English (en)
Inventor
Martin Pass
John Peter Bailey
Michael Brian Giles
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20070655L publication Critical patent/NO20070655L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Oppfinnelsen angår pyrimidinderivater med formel I hvor hver av p, R1 , R2, q, R3 , r, R4 , X1 og Q1 har hvilken som helst av betydningene definert i beskrivelsen; fremgangsmåter for deres fremstilling, farmasøytiske preparater inneholdende dem og anvendelse av dem ved 3 fremstilling av et medikament for anvendelse for produksjon av en anti-proliferativ effekt hos et varmblodig dyr så som mennesker.
NO20070655A 2004-07-09 2007-02-05 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft NO20070655L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0415365.6A GB0415365D0 (en) 2004-07-09 2004-07-09 Pyrimidine derivatives
PCT/GB2005/002664 WO2006005914A1 (en) 2004-07-09 2005-07-07 2, 4, 6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer

Publications (1)

Publication Number Publication Date
NO20070655L true NO20070655L (no) 2007-03-21

Family

ID=32865683

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070655A NO20070655L (no) 2004-07-09 2007-02-05 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft

Country Status (15)

Country Link
US (1) US20080058332A1 (no)
EP (1) EP1768978B1 (no)
JP (1) JP2008505875A (no)
CN (1) CN101014590A (no)
AT (1) ATE400570T1 (no)
AU (1) AU2005261551A1 (no)
BR (1) BRPI0513058A (no)
CA (1) CA2571748A1 (no)
DE (1) DE602005008065D1 (no)
GB (1) GB0415365D0 (no)
IL (1) IL180136A0 (no)
MX (1) MX2007000119A (no)
NO (1) NO20070655L (no)
WO (1) WO2006005914A1 (no)
ZA (1) ZA200700054B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05005477A (es) 2002-11-21 2005-07-25 Chiron Corp Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-cinasa y su uso en el tratamiento del cancer.
GB0415364D0 (en) 2004-07-09 2004-08-11 Astrazeneca Ab Pyrimidine derivatives
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
GB0525080D0 (en) * 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
GB0525083D0 (en) * 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
GB0525081D0 (en) * 2005-12-09 2006-01-18 Astrazeneca Ab Pyrimidine derivatives
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
CA2653733A1 (en) * 2006-05-26 2007-12-06 University Of Louisville Research Foundation, Inc. Macrophage migration inhibitory factor antagonists and methods of using same
AU2007287428B2 (en) * 2006-08-24 2011-08-11 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
WO2008032041A1 (en) * 2006-09-14 2008-03-20 Astrazeneca Ab Pyrimidine derivatives having inhibitory activity against pi3k enzymes
CN101711241A (zh) * 2007-02-06 2010-05-19 诺瓦提斯公司 Pi3-激酶抑制剂和它们的使用方法
JP2010533159A (ja) * 2007-07-09 2010-10-21 アストラゼネカ アクチボラグ 化合物９４７
ATE554075T1 (de) * 2007-07-09 2012-05-15 Astrazeneca Ab Bei mit mtor-kinase und/oder pi3k in zusammenhang stehenden krankheiten angewendete morpholinopyrimidinderivate
WO2010120994A2 (en) * 2009-04-17 2010-10-21 Wyeth Llc Ureidoaryl-and carbamoylaryl-morpholino- pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their synthesis
PL2448927T3 (pl) 2009-07-02 2014-09-30 Sanofi Sa Nowe pochodne (6-okso-1,6-dihydro-pirymidyn-2-ylo)-amidu, ich wytwarzanie i ich zastosowanie farmaceutyczne jako inhibitorów fosforylacji AKT
EP2480235A4 (en) 2009-09-24 2013-05-08 Univ Louisville Res Found NEW IODO-PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ILLNESSES AND SUFFERING IN CONNECTION WITH THE MACROPHAGE MIGRATION-INHIBITING FACTOR
RS53827B1 (en) 2009-11-02 2015-06-30 Pfizer Inc. DIOKSA-BICYCLE DERIVATIVES [3.2.1] OCTOBER-2,3,4-TRIOLA
US9155790B2 (en) 2010-05-20 2015-10-13 University of Lousiville Research Foundation, Inc. Methods and compositions for modulating ocular damage
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
PE20141581A1 (es) 2011-09-27 2014-11-14 Novartis Ag 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
PE20151939A1 (es) 2013-03-14 2016-01-08 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
CN104151256B (zh) * 2014-08-14 2016-08-24 西安交通大学 二取代苯甲酰胺类化合物及其合成方法和应用
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
CN107793365B (zh) * 2016-08-31 2021-08-17 上海微创医疗器械（集团）有限公司 一种化合物及其制备方法和用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19836697A1 (de) * 1998-08-13 2000-02-17 Hoechst Marion Roussel De Gmbh Substituierte 4-Amino-2-aryl-pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
KR100774855B1 (ko) * 2000-04-27 2007-11-08 아스텔라스세이야쿠 가부시키가이샤 축합 헤테로아릴 유도체

Also Published As

Publication number Publication date
IL180136A0 (en) 2007-06-03
US20080058332A1 (en) 2008-03-06
MX2007000119A (es) 2007-03-09
GB0415365D0 (en) 2004-08-11
CN101014590A (zh) 2007-08-08
ATE400570T1 (de) 2008-07-15
JP2008505875A (ja) 2008-02-28
EP1768978A1 (en) 2007-04-04
DE602005008065D1 (de) 2008-08-21
ZA200700054B (en) 2008-05-28
AU2005261551A1 (en) 2006-01-19
WO2006005914A1 (en) 2006-01-19
BRPI0513058A (pt) 2008-04-22
EP1768978B1 (en) 2008-07-09
CA2571748A1 (en) 2006-01-19

Similar Documents

Publication Publication Date Title
NO20070655L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
NO20070656L (no) 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft
NO20070681L (no) 2, 4, 6-Trisubstituterte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse i behandling av kreft
NO20090631L (no) Morpholin pyrimidin derivativer anvendelige i behandlingen av proliferative lidelser
NO20071246L (no) Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer.
NO20071245L (no) Kinazolinonderivater og deres anvendelse som b-RAF-inhibitorer.
NO20066081L (no) Kinazolinderivater som erbB-reseptortyrosinkinaser
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
NO20081729L (no) Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer
TNSN06411A1 (en) Pyrimidine urea derivatives as kinase inhibitors
NO20081315L (no) Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
NO20061743L (no) Kinazolinderivater
NO20085176L (no) Fenyl substituerte heteroaryl-derivater og andvendelse som anti-tumor agenter
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20073719L (no) Kjemiske forbindelser
NO20084202L (no) 4-anilinoquinolin-3-carboksamider som CSF-1R kinase inhibitorer
NO20091683L (no) Kjemiske forbindelser
WO2006106326A8 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
NO20090025L (no) Pyrrolotriazinkinaseinhibitorer
NO20064062L (no) Prodroger av piperazin og substituerte piperidin antivirale midler
NO20071776L (no) Kinoksaliner som B RAF inhibitorer.
NO20082730L (no) Morfolinopyrimidinderivater og deres anvendelse i terapi
NO20083845L (no) 2,4-diaminopyrimidiner som celle-cyklus kinase inhibitorer
NO20081893L (no) 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft
NO20072784L (no) Pyridenkarboksamidderivater for anvendelse som anticancer midler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application